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Abstract
In addition to genetic alterations, epigenetic abnormalities have been shown to underlie the
pathogenesis of acute lymphoblastic leukemia (ALL)—the most common pediatric cancer.
The purpose of this study was to characterize the whole genome DNA methylation profile in
children with precursor B-cell ALL (BCP ALL) and to compare this profile with methylation
observed in normal bone marrow samples. Additional efforts were made to correlate the
observed methylation patterns with selected clinical features. We assessed DNA methyla-
tion from bone marrow samples obtained from 38 children with BCP ALL at the time of
diagnosis along with 4 samples of normal bone marrow cells as controls using Infinium
MethylationEPIC BeadChip Array. Patients were diagnosed and stratified into prognosis
groups according to the BFM ALL IC 2009 protocol. The analysis of differentially methylated
sites across the genome as well as promoter methylation profiles allowed clear separation
of the leukemic and control samples into two clusters. 86.6% of the promoter-associated dif-
ferentially methylated sites were hypermethylated in BCP ALL. Seven sites were found to
correlate with the BFM ALL IC 2009 high risk group. Amongst these, one was located within
the gene body of the MBP gene and another was within the promoter region- PSMF1 gene.
Differentially methylated sites that were significantly related with subsets of patients with
ETV6-RUNX1 fusion and hyperdiploidy. The analyzed translocations and change of genes’
sequence context does not affect methylation and methylation seems not to be a mecha-
nism for the regulation of expression of the resulting fusion genes.







Citation: Chaber R, Gurgul A, Wro´bel G, Haus O,
Tomoń A, Kowalczyk J, et al. (2017) Whole-
genome DNA methylation characteristics in
pediatric precursor B cell acute lymphoblastic
leukemia (BCP ALL). PLoS ONE 12(11): e0187422.
https://doi.org/10.1371/journal.pone.0187422
Editor: Obul Reddy Bandapalli, German Cancer
Research Center (DKFZ), GERMANY
Received: July 4, 2017
Accepted: October 19, 2017
Published: November 10, 2017
Copyright: © 2017 Chaber et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This study was supported by the grant of
the National Science Centre, Poland, https://www.
ncn.gov.pl/, grant no. 2011/01/B/NZ4/03345. The
funding was received by author IZ. The funder had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer with 3–5 cases per
100,000 with a peak of incidence 2–5 years [1]. Most of these cases (80–85%) originate from
precursor B cells, BCP ALL [2]. The initiation of BCP ALL (as with other ALL’s) is driven by
genetic alterations including point mutations, chromosome amplifications or translocations
which ultimately lead to abnormal expression of key genes responsible for cell proliferation
and differentiation [3]. Indeed, leukemic cells in ~75% of patients contain some chromosome
abnormalities. Some of these abnormalities have prognostic significance. For example, genetic
changes with good prognosis include hyperdiploidy with greater than 50 chromosomes or
translocation t(12;21) ETV6-RUNX1 (TEL-AML1) which are detected in about a quarter of
cases of childhood BCP ALL [4]. Hypodiploidy with fewer than 44 chromosomes and chromo-
somal rearrangements including translocation t(9;22) BCR-ABL1, rearrangement of MLL at
11q23 to a diverse range of fusion partners and internal amplification of chromosome 21
(iAMP 21) are less common (1–6% of cases) but are prognostic of a significantly higher risk of
relapse and poor outcome. There are also chromosomal abnormalities as t(1;19)(q23;p13) or
TCF3-PBX1 (formerly known as E2A-PBX1) (4% cases) with uncertain prognostic significance
[4,5].
In addition to identifiable chromosomal abnormalities, many other recurring genetic alter-
ations have been reported. The most prevalent submicroscopic alterations in pediatric ALL
occur in CDKN2A/B (30–40%), IKZF1 (15%), PAX5 (20%), and ETV6 (10–15%). Most of these
lesions have not been shown to impact prognosis. Mutations or deletions of IKZF1, located at
7p12, have, however, been shown to be independent predictors of outcome [5–8].
In addition to these genetic alterations, epigenetic abnormalities such as DNA methylation,
post-translational histone protein modifications and interaction with non-coding RNA
(miRNA or siRNA) have been shown to underlie the pathogenesis of ALL [9]. DNA methyla-
tion is a reversible process of attaching methyl residues to cytosine by the action of DNA
methyltransferases—DNMT1, DNMT3a, DNMT3b. The methylation of cytosine’s located
among CpG dinucleotides is significant for the control of gene expression. Such CpG sites
may be dispersed amongst the whole genome but they frequently appear together in, so-called,
CpG islands that are found within 70% of gene promoters [10] and are particularly common
within the promoters of genes responsible for cell cycle control and cellular metabolism [11].
CpG islands are generally not methylated and methylation can inhibit gene expression both
directly, through the prevention of transcription factors or RNA I polymerase binding, and
indirectly by impacting on histone modification or chromatin remodeling proteins [12]. Aber-
rant methylation of CpG islands for the genes associated with DNA repair (hMLH1, MGMT),
cell cycle control (p16INK4A, p15INK4B, p14ARF), apoptosis (DAPK) or detoxification
(GSTP1) [11] can initiate carcinogenesis [11,13,14] including leukemogenesis [14–17].
The purpose of this study was to describe and characterize the whole genome DNA methyl-
ation profile in children with BCP ALL and to compare this with methylation profile obtained
in normal bone marrow samples. The secondary aim was to correlate the methylation land-
scape with some biological and clinical features as characteristic of patients, cytogenetic aber-
rations and prognosis based on treatment protocol criteria.
Material and methods
Patients
Samples of bone marrow were obtained from 38 patients with pediatric BCP ALL at the time
of diagnosis. The characteristics of patients are shown in Table 1. Ethics Committee approval
was obtained from the Institutional Review Board of the Medical University of Lodz (number,
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RNN/226/11/KE). Informed consent has been obtained from parents/legal guardians of all the
participating children. Various genetic aberrations were detected among most of the patients.
The patients were stratified into prognostic groups according to the BFM ALL IC 2009 proto-
col [18]. This stratification is based on the initial clinical features including patient age, white-
blood cells count at diagnosis, presence of specific genetic aberrations, the response to steroids
at day 8, the cytomorphological response in bone marrow at day 15 and 33 and the minimal
residual disease level at day 15.
Samples of normal bone marrow cells were examined as controls. These bone marrow sam-
ples were obtained during routine diagnostic procedures of other diseases (sideropenic ane-
mia, localized Wilms tumor and localized lipofibromatosis) from 4 patients (2 male, 2 female,
age 5–17 years). In each case, the bone marrow as well as microscopic examination of periph-
eral blood smears revealed no pathology.
Samples and DNA methylation profiling
DNA was purified using QIAamp DNA Blood Mini Kit (QIAGEN), examined for integrity by
agarose gel electrophoresis and quantified using Qubit 2.0 fluorimeter using a double stranded
DNA (BR) assay (Thermo Fisher Scientific). About 500 ng of the sampled DNA was analyzed
on a Infinium1 MethylationEPIC BeadChip (Illumina, San Diego, CA). The analysis com-
prised bisulfite conversion of DNA with EZ DNA Methylation™ Kit (Zymo Research) using
modified thermal conditions (as recommended by the supplier). Purified converted DNA was








high risk- HRG 5
intermediate risk- IRG 26
standard risk- SRG 7
the central nervous system involvement 3
relapse 1
death 2
prednisone poor responder 3
hematological remission at day 33 38
observation time 6–36 months
cytogenetic aberrations
Hyperdiploidy (>50 chromosomes) 13
t(12;21) with fusion ETV6-RUNX1 7





* according ALL IC-BFM 2009 protocol [18]
https://doi.org/10.1371/journal.pone.0187422.t001
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then used as an input to Infinium HD Assay Methylation Protocol (Illumina). The hybridized
and stained arrays were ultimately scanned using HiScanSQ system (Illumina). The Infinium
MethylationEPIC BeadChip used enabled the analysis of more than 850,000 methylation sites
per sample which cover the broad content categories, including sites: within known CpG
islands, outside of CpG islands, Non-CpG methylated sites identified in human stem cells
(CHH sites), differentially methylated (DM) sites identified in tumor versus normal (multiple
forms of cancer) and across several tissue types, FANTOM5 enhancers, ENCODE open chro-
matin and enhancers, DNase hypersensitivity sites and miRNA promoter regions. Moreover,
the array content covers >90% of content contained on the previous Illumina HumanMethy-
lation450 BeadChip.
Data quality control and analysis
The raw intensity data were assessed for quality using BeadArray Controls Reporter (Illu-
mina). Next, the obtained IDAT files were analyzed using the Chip Analysis Methylation Pipe-
line (ChAMP) [19] for EPIC array data. During initial data handling, probes with p-value
<0.01 and with fewer than 3 beads in at least 5% of samples were excluded. Additionally, non-
CpG probes, SNP-related probes, multi-hit probes and probes located in chromosome X and
Y were also removed. The beta values for 800,619 probes per sample were then calculated and
checked for quality by evaluation of a beta multidimensional salting (MDS) plot and a density
plot across the study groups. The beta value is defined as a proportion of DNA methylation at
a particular CpG site (also called the methylation beta-value (β)) which is ascertained by taking
the ratio of the methylated (C) to unmethylated (T) signals, using the formula: β = intensity
of the methylated signal/(intensity of the unmethylated signal + intensity of the methylated sig-
nal + 100). A β-value of 0 represents an unmethylated CpG site and a β-value approaching 1
represents a fully methylated CpG site.
The obtained beta values were then normalized using the BMIQ method [20] and the singu-
lar value decomposition method (SVD) implemented by Teschendorff et al. (2009) [21] was
used to identify the most significant causes of variation, including technical variation (batch
effects like: slide, array or sample well). Batch effects (if detected for separate comparisons)
were removed using the ComBat algorithm which uses an empirical Bayes method designed to
correct data for technical variation [22].
Differential probes methylation between groups was calculated using the champ.DMP()
function which uses the Limma package [23] to calculate the p-value for differential methyla-
tion using a linear model. The DMP detecting t-test p-values were corrected for multiple test-
ing using the Benjamin-Hochberg procedure [24].
Differential methylation analysis was performed in three setups: to identify the general dif-
ferences between all BCP ALL patients and the controls, second to identify sites/regions differ-
entially methylated between SRG/IRG and HRG patients and third detecting methylation sites
associated with recurrent genetic abnormalities. Additional pairwise comparisons have been
made within BCP ALL patients group to detect sites which may be associated with confound-
ing factors such as age (6 vs.>6 years of age) or gender (males vs. females). Differences in
the distribution of CpG sites across different genomic classes (gene bodies, IGR, promoters,
CpG islands etc.) were evaluated using Chi-square test.
Functional genes annotation and analysis
The genes associated with specific differentially methylated (DM) sites were analyzed in terms
of molecular functions, biological presses, cellular components, pathways and phenotypes
using WebGestalt (WEB-based GEne SeT AnaLysis) toolkit, exploiting an information
Whole-genome DNA methylation in pediatric BCP ALL
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obtained from GO, KEGG, WikiPathways, Human Phenotype Ontology and PharmGKB data-
bases. Enrichment analysis was performed with respect to all known human genes (genome),
identifying enriched categories with corrected p-value (according to Benjamin-Hochberg pro-
cedure) lower than 0.01 and requiring at least 4 genes per enriched category.
Results
General assay performance and CpG statistics
The general assay performance was validated using control probes and no issues were found
with the samples. After initial filtration, the beta values of 800,619 probes were normalized and
batch effect was identified (slide, array and sample well) within the data by evaluation of com-
ponents of variation. After normalization for technical variation, SVD indicated that the only
source of variation amongst the sample groups was inter-group differentiation. Among the
valid probes, representing individual CpG sites, 295,458 were located within genes (genes
body), 228,710 in intergenic regions (IGR) and 67,841 in genes’ 5’UTR. Promoter associated
sites, defined as: TSS200 (0–200 nucleotides (nt) upstream of the transcription start site) and
TSS1500 (200–1500 nt upstream of TSS) were represented by 98,881 and 60,483 CpGs, respec-
tively. 150,080 analyzed probes were located within known CpG islands, 142,693 in “shores”
(up to 2000 bp from island) and 453,065 probes were located outside CpG islands (open sea).
Genome wide differential methylation analysis between BCP ALL and
control
The DNA methylation status of 800,619 CpG loci distributed across the genome was interro-
gated in 38 pediatric BCP ALL patients and four non-leukemic control samples. A common
set of 118,871 probes, mapped to 17,885 unique genes (promoters and gene bodies) or inter-
genic regions, were found to be differentially methylated (adjP<0.05; DM) in the patient’s rela-
tive to controls, suggesting the presence of distinct BCP ALL-associated DNA methylation
signature (S1 Appendix). The absolute Δβ value for separate DM probes (calculated as an abso-
lute difference between averaged β-values for separate groups) ranged from 0.009 to 0.730 with
a mean of 0.216. Applying principal component analysis (PCA) to the differentially methylated
site data shows clear separation of leukemic and control methylation profiles, with a higher
level of profile variation observed amongst the BCP ALL samples (Fig 1). DM sites are uni-
formly distributed across the genome (Fig 2 as a Manhattan plot of -log10p-values for differen-
tially methylated probes).
Of the 118,871 sites differentially methylated between leukemic and control samples, 67,115
(56%) were hypermethylated in BCP ALL samples and 51,756 (44%) were hypomethylated.
The annotation analysis and comparison of hypo- and hypermethylated CpG features showed
that genome-wide hypermethylation in leukemic DNA is more commonly associated with
CpG islands and regions in close vicinity of transcription start site (TSS200 and 1st exon),
whereas hypomethylation is more common in gene bodies and regions outside CpG islands
(open-sea) (Fig 3, Table 2). The differences in distribution of hyper- and hypomethylated sites
among separate genomic regions were statistically significant for all CpG context classes (as
shown by Chi-square test; p<0.001).
Differential methylation analysis of genes’ promoters in BCP ALL and
control samples
To characterize changes in methylation profile of genes’ promoters accompanying leukemia
progression, we focused on a differentially methylated CpGs (BCP ALL vs. CTR) located in
Whole-genome DNA methylation in pediatric BCP ALL
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regions upstream from transcription start sites (TSS200, TSS1500), within CpG islands or in
their direct vicinity (island shore; ±2000 bp). DM sites were additionally filtered to remove
those with absolute Δβ value between groups lower than 0.3. This resulted in selection of 5,465
DM CpGs of which 2,611 (47.8%) were in a range of 200 bp from TSS and the remaining 2,854
were in regions from 200 to 1500 bp from TSS. The majority of the sites (3,451; 63.1%) were
positioned within CpG island cores and the remaining were in regions upstream or down-
stream of the islands (island shores; 2,014 CpGs). The average absolute Δβ value for the pro-
moters-associated sites after filtration was 0.399 (±0.076).
The vast majority of the promoter-associated DM sites (4733; 86.6%) were hypermethylated
in leukemia when compared to healthy control. Hypermethylated CpGs were located both in
TSS200 (53.4%) and TSS1500 (46.6%) promoter regions and were mainly found within CpG
islands (72.5%), whereas hypomethylated sites occurred predominantly in regions positioned
further away from TSS (TSS1500; 88.7%) and outside of CpG islands (island shores; 97.5%).
Unsupervised hierarchical clustering (based on Euclidean distance) of the promoter meth-
ylation profiles showed clear separation of the leukemic and non-leukemic samples into two
visible clusters (Fig 4) proving the existence of distinct methylation patterns amongst genomic
Fig 1. PCA based on 118,871 sites differentially methylated between BCP ALL and control samples.
https://doi.org/10.1371/journal.pone.0187422.g001
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Fig 2. Genomic distribution of CpGs with significant differences in methylation level between BCP ALL and control in gene
context.
https://doi.org/10.1371/journal.pone.0187422.g002
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promoters. Some variation was also observed within BCP ALL group with visible separation of
three leukemic samples.
Identification of a leukemia-characteristic methylation profile
To find the most uniform and distinct from physiological methylation signature for leuke-
mia, additional filtering criteria of all probes differentially methylated between BCP ALL and
control were applied. The procedure aimed to identify CpGs with the lowest methylation
level variation amongst BCP ALL samples (beta values standard deviation <0.05 within BCP
ALL group) and with the largest difference in methylation level with respect to the control
(delta beta absolute value >0.3). This filtration step allowed a set of 265 DM CpGs to be iden-
tified, with the most uniform and distinct from the methylation profile of the non-leukemic
samples. As expected, unsupervised hierarchical clustering based on these probes enabled
clear separation of the leukemic and non-leukemic methylation profiles and demonstrated
high profile uniformity across BCP ALL samples (Fig 5) with minor discrepancies found for
Fig 3. Distribution of hyper- and hypomethylated sites differentially methylated between leukemic
and control samples.
https://doi.org/10.1371/journal.pone.0187422.g003
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Table 2. Genomic distribution of probes differentially methylated between leukemic and control samples with respect to CpG island and gene
context.
Centex Differentially methylated sites
between BCP ALL and control
Differentially methylated between BCP ALL and control with subdivision into hyper-
and hypo-methylated sites
Region No of probes % of probes No of Hyper- in BCP ALL % of Hyper- No of Hypo- in BCP ALL % of Hypo-
Gene context
1stExon 3719 3.1 2929 4.4 790 1.5
3’UTR 2591 2.2 1280 1.9 1311 2.5
5’UTR 10536 8.9 5779 8.6 4757 9.2
Body 44674 37.6 23388 34.8 21286 41.1
ExonBnd 635 0.5 330 0.5 305 0.6
IGR 35673 30.0 19831 29.5 15842 30.6
TSS1500 13004 10.9 7552 11.3 5452 10.5
TSS200 8039 6.8 6026 9.0 2013 3.9
CpG island context
island 23323 19.6 20369 30.3 2954 5.7
opensea 67759 57.0 32128 47.9 35631 68.8
shelf 7665 6.4 3362 5.0 4303 8.3
shore 20124 16.9 11256 16.8 8868 17.1
Gene/island context
1stExon-island 2473 2.1 2247 3.3 226 0.4
1stExon-opensea 732 0.6 344 0.5 388 0.7
1stExon-shelf 49 0.0 25 0.0 24 0.0
1stExon-shore 465 0.4 313 0.5 152 0.3
3’UTR-island 257 0.2 183 0.3 74 0.1
3’UTR-opensea 1593 1.3 780 1.2 813 1.6
3’UTR-shelf 252 0.2 86 0.1 166 0.3
3’UTR-shore 489 0.4 231 0.3 258 0.5
5’UTR-island 2376 2.0 2063 3.1 313 0.6
5’UTR-opensea 5433 4.6 2459 3.7 2974 5.7
5’UTR-shelf 883 0.7 355 0.5 528 1.0
5’UTR-shore 1844 1.6 902 1.3 942 1.8
Body-island 5650 4.8 4718 7.0 932 1.8
Body-opensea 29807 25.1 14168 21.1 15639 30.2
Body-shelf 3361 2.8 1502 2.2 1859 3.6
Body-shore 5856 4.9 3000 4.5 2856 5.5
ExonBnd-island 19 0.0 13 0.0 6 0.0
ExonBnd-opensea 541 0.5 279 0.4 262 0.5
ExonBnd-shelf 33 0.0 19 0.0 14 0.0
ExonBnd-shore 42 0.0 19 0.0 23 0.0
IGR-island 5029 4.2 4621 6.9 408 0.8
IGR-opensea 24351 20.5 11634 17.3 12717 24.6
IGR-shelf 2548 2.1 1165 1.7 1383 2.7
IGR-shore 3745 3.2 2411 3.6 1334 2.6
TSS1500-island 3052 2.6 2605 3.9 447 0.9
TSS1500-opensea 3482 2.9 1531 2.3 1951 3.8
TSS1500-shelf 351 0.3 136 0.2 215 0.4
TSS1500-shore 6119 5.1 3280 4.9 2839 5.5
TSS200-island 4467 3.8 3919 5.8 548 1.1
TSS200-opensea 1820 1.5 933 1.4 887 1.7
(Continued )
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two leukemic samples diagnosed as BCP ALL with prodromal, preleukemic phase. This
observation was also confirmed by PCA which showed that with the use of filtered probes set,
low and lower than in control group level of methylation profile variation was observed in
BCP ALL (Fig 6).
The potentially leukemia-characteristic DM sites were distributed on all 22 autosomes and
were predominately located in gene bodies (48.7%) or intergenic regions (26.8%) and most
(83.0%) were distributed in regions outside of CpG islands (open sea). The hypermethylated
sites (n = 177; 66.8%) showed similar regional distribution as hypomethylated with slightly
Table 2. (Continued)
Centex Differentially methylated sites
between BCP ALL and control
Differentially methylated between BCP ALL and control with subdivision into hyper-
and hypo-methylated sites
Region No of probes % of probes No of Hyper- in BCP ALL % of Hyper- No of Hypo- in BCP ALL % of Hypo-
TSS200-shelf 188 0.2 74 0.1 114 0.2
TSS200-shore 1564 1.3 1100 1.6 464 0.9
Probes distribution in separate categories differed significantly across whole table with p<0.001
https://doi.org/10.1371/journal.pone.0187422.t002
Fig 4. Unsupervised hierarchical clustering of promoter regions-associated methylation profiles in
leukemic and control samples.
https://doi.org/10.1371/journal.pone.0187422.g004
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increased share of probes located within gene bodies. The detailed statistics on the selected
CpG are presented in S2 Appendix.
CpG associated with leukemia risk (SRG/IRG vs. HRG)
To find CpG sites which methylation level is associated with leukemia risk, the BCP ALL cases
were stratified into two groups, encompassing HRG and combined SRG/IRG patients accord-
ing to the BFM ALL IC 2009 protocol [18]. Statistical analysis showed, that of the 800,619 CpG
analyzed sites, only 14 differed in methylation level between the groups. Most of these sites
(n = 10; 71.4%) were hypomethylated in HRG. The average absolute Δβ for these sites was low
with a mean of 0.232 (±0.058). Eight of the differentially methylated CpGs were located in
intergenic regions and only two were found within promoter regions (TSS1500). Another
three DM CpG were positioned within gene bodies. The list of DM sites between HRG and
SRG/IRG is presented in S3 Appendix.
The most important CpG sites for prognosis were identified using a lasso penalized logistic
regression [25]. This identified seven sites which are correlated with prognosis. Six of these
relate to high-risk group stratification with poorer prognosis when they were hypomethylated
and one if hypermethylated (Fig 7a). Among these selected CpG two were located within
Fig 5. Unsupervised hierarchical clustering of methylation profiles with probes selected to minimize
variation among leukemic samples.
https://doi.org/10.1371/journal.pone.0187422.g005
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genes body or were promoter region-related (corresponding to MBP and PSMF1 gene) and
five are found in intergenic regions.
Age and gender-related methylation changes in leukemia patients
Age and gender-related changes in CpG methylation in leukemia patients were identified in
two separate comparisons by the stratification of BCP ALL group according to sex and age
(6 and>6 years of age). A MDS analysis based on 1000 the most variable sites did not show
clear stratification of methylation profiles according to these two conditions (Fig 8).
The identification of DM probes between separate subgroups allowed 113 sites (connected
with 50 different genes) that differ in methylation depending on sex and 66 (36 genes) con-
nected with age. Of the gender-related sites, 77 (68.1%) were hypermethylated in females with
low level of methylation differences between sexes, expressed by a mean absolute Δβ of 0.143.
The age-related changes were mostly linked with hypermethylation of CpGs, with almost 85%
Fig 6. PCA based on filtered probes set minimizing the variation of methylation profiles in leukemic samples.
https://doi.org/10.1371/journal.pone.0187422.g006
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of probes showing higher methylation levels in older patients. The extent of age related methyl-
ation was higher than this observed for sex, with mean absolute delta beta of 0.329 (±0.073).
Only three of the sex-related DM sites and seven of the age-related sites have been found
among previously detected 118,871 CpGs differing in methylation levels between BCP ALL
cases and controls, suggesting that age and sex are not important confounding factors for the
methylation profile differentiation of pediatric leukemia.
Fig 8. Multidimensional scaling analysis based on 1000 the most variable sites with respect to: A—gender, B—age.
https://doi.org/10.1371/journal.pone.0187422.g008
Fig 7. Results of Ridge Regression of a high risk of a patient in the analyzed data set. Each curve
corresponds to a variable. It shows how much this variable contributes to the prediction of high risk of patient
(a), hyperdiploidy (b) and t(12;21) ETV6-RUNX1 (c) aberrations in analyzed data set. Numbers on the left are
coefficients and numbers on top are total count of variables selected for an L1 Norm (statistical parameter)
shown on the bottom.
https://doi.org/10.1371/journal.pone.0187422.g007
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Changes in methylation patterns associated with recurrent genetic
abnormalities in childhood ALL
To find methylation profiles distinctive for genetic BCP ALL subtypes, patients were stratified
into groups with ETV6-RUNX1 (n = 7), TCF3-PBX1 (n = 3), IGH (n = 3), hyperdiploidy
(n = 13) and triploidy (n = 3) cytogenetic variants. Differentially methylated sites were identi-
fied in pairwise comparisons of specific genetic subtype with all other patients with known
cytogenetic status, including eight patients without major chromosomal aberrations. Differen-
tial methylation analysis identified from 117 to 6,977 sites for the separate genetic subtypes. Of
these, only a few (up to 67) overlapped between the separate groups. All analyzed subtypes
were associated with hypomethylation with respect to the remaining patients with the highest
proportion of hypomethylated sites found in IGH, hyperdiploidy and triploidy aberration car-
riers (from 72 to 77%) (Table 3). The distribution of DM sites across the genome was generally
similar for separate subtypes, however, some evidence for an increased number of DM sites in
the TSS1500 promoter regions in IGH carries have been found. The highest differences in
methylation level compared to remaining BCP ALL cases, measured as average Δβ (0.384)
were observed for TCF3-PBX1 genetic subtype (Table 3). The DM sites were related to 74 to
2963 unique genes depending on genetic abnormality and total number of detected DM sites.
These genes are associated with a broad range of KEGG pathways, of which the top ten are
Table 3. Statistic of sites differentially methylated between specific genetic subtypes of leukemia and remaining BCP ALL patients with known
cytogenetic status.
Genetic subtype
ETV6-RUNX1 TCF3-PBX1 IGH Hyperdiploidy Triploidy
Number of DM sites
All DM sites 5207 6977 117 4401 347
Percentage of hyper-/hypomethylated sites
Hyper- 40.3 36.2 23.1 27.5 24.8
Hypo- 59.7 63.8 76.9 72.5 75.2
Localization in gene context (% of all sites)
1stExon 3.5 1.4 0.9 1.5 3.2
3’UTR 2.0 2.9 5.1 2.1 0.9
5’UTR 12.5 8.6 6.0 7.3 11.0
Body 36.5 44.3 28.2 39.6 33.7
ExonBnd 0.4 0.8 3.4 0.7 1.2
IGR 26.9 28.6 33.3 36.3 29.4
TSS1500 10.4 8.9 19.7 8.9 11.0
TSS200 7.7 4.5 3.4 3.7 9.8
Localization in CpG island context (% of all sites)
island 21.6 9.6 7.7 7.1 16.4
opensea 55.7 66.2 65.0 75.6 60.5
shelf 7.0 8.1 5.1 5.6 7.2
shore 15.7 16.1 22.2 11.7 15.9
Average difference in methylation
all 0.272 0.384 0.208 0.243 0.171
hyper 0.252 0.37 0.209 0.252 0.144
hypo -0.285 -0.392 -0.207 -0.239 -0.179
Number of associated genes
Unique genes 2065 2963 74 1836 205
https://doi.org/10.1371/journal.pone.0187422.t003
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presented in Table 4. The list of DM probes along with their annotation and associated genes
is presented in S4 Appendix.
To determine the abilities of the sites that differed between separate genetic subtypes, from
each comparison the top 100 DM sites (with the lowest adjusted p-value) were selected and a
common panel of 500 sites was created with potential differentiation and diagnostic abilities.
Unsupervised hierarchical clustering of the methylation level of selected probes allowed visible
separation of ETV6-RUNX1 and TCF3-PBX1 profiles and classification of the remaining sub-
types into mixed clusters with clear homogeneity (Fig 9). The three dimensional PCA plot
allowed to clearly distinguish genetic leukemia subtypes associated with ETV6-RUNX1 and
TCF3-PBX1 variants with visible separation of clusters including hyperdiploidy cases and the
separation of a single case with IGH/triploidy aberrations (Fig 10). The list of probes used to
distinguish the genetic BCP ALL subtypes are presented in S5 Appendix.
An additional analysis was performed to explore the methylation profile of genes that are
substrates of the most common chromosomal translocations found in the studied BCP ALL
cases. The methylation profile of ETV6 and RUNX1 (TEL-AML1) genes was found to be vari-
able across gene bodies, but showed visible demethylation within CpG islands located in pro-
moter regions (both in BCP ALL and control patient groups) (Fig 11). Several sites across the
ETV6 and RUNX1 genes differ significantly at a pointwise level between BCP ALL and the con-
trol group. Few of these however, differ between BCP ALL patients and BCP ALL cases with
ETV6-RUNX1 aberration. Within the RUNX1 gene, demethylation was observed within two
alternative gene promoters with clear hypermethylation of the gene body. The most pro-
nounced differences in methylation level between BCP ALL and the control group were
observed within the CpG island located in the central part of the RUNX1 gene, which is an
alternative gene promoter (P2). This region, however, did not show noticeable differences in
methylation level between BCP ALL and BCP ALL-ETV6-RUNX1 carriers.
A similar methylation pattern (demethylation of promoters and visible hypermethylation
of gene bodies) was found for the TCF3 and PBX1 (E2A-PBX1) genes involved in t(1;19)(q23;
p13) chromosomal rearrangement. The methylation profile of the genes was similar between
BCP ALL, control and TCF3-PBX1 rearrangement carriers, except the north-shore part of
the CpG island located near the transcription start site of the TCF3 gene shows hypermethyla-
tion in control group with respect to the BCP ALL patients (genome-wide adjusted p<0.05)
(Fig 12).
It was possible using the lasso penalized logistic regression analysis to extract some DM
sites related significantly with subsets of patients with ETV6-RUNX1 and hyperdiploidy (Fig
7b and 7c). Among these sites, some were localized with promoter regions or gene bodies. The
most important functional DM sites in particular subgroups are summarized in Table 5. These
DM sites can potentially distinguish the groups with analyzed chromosomal aberrations after
being confirmed in future studies with a larger patient cohort. The other cytogenetic aberra-
tions were not analyzed using this method due to an insufficient number of affected patients.
Discussion
A distinct DNA methylation pattern of leukemic samples
The normal hematopoietic tissue in bone marrow consists of a variety of cell types including
the blood cells and their precursors at different developmental stages derived from pluripoten-
tial, self-renewing stem cells and the microenvironment’s cells like adventitial reticular cells,
endothelial cells, macrophages, adipocytes, bone lining cells (e.g., osteoblasts). During blood-
cell development, pluripotent stem cells undergo either self-renewal or differentiation into
multilineage committed progenitor cells: myeloid stem cells which can then differentiate into
Whole-genome DNA methylation in pediatric BCP ALL
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Table 4. Top ten KEGG pathways connected with genes containing sites differentially methylated between specific genetic subtype and remain-
ing BCP ALL patients.
ID Name Number of Genes FDR
ETV6-RUNX1
hsa05200 Pathways in cancer 83 2.24E-09
hsa04724 Glutamatergic synapse 31 0.0000131
hsa04713 Circadian entrainment 27 0.0000284
hsa04728 Dopaminergic synapse 32 0.0000489
hsa04723 Retrograde endocannabinoid signaling 27 0.000052
hsa04360 Axon guidance 38 0.000118
hsa04015 Rap1 signaling pathway 42 0.000268
hsa04925 Aldosterone synthesis and secretion 22 0.000282
hsa04921 Oxytocin signaling pathway 34 0.000282
hsa04659 Th17 cell differentiation 26 0.000282
TCF3-PBX1
hsa04071 Sphingolipid signaling pathway 38 0.000254
hsa04070 Phosphatidylinositol signaling system 32 0.000391
hsa04360 Axon guidance 48 0.000391
hsa05200 Pathways in cancer 89 0.000391
hsa04144 Endocytosis 62 0.00125
hsa04921 Oxytocin signaling pathway 42 0.00168
hsa04072 Phospholipase D signaling pathway 39 0.00168
hsa04520 Adherens junction 24 0.0021
hsa05221 Acute myeloid leukemia 20 0.0021
hsa04066 HIF-1 signaling pathway 30 0.0021
IGH
hsa04730 Long-term depression 2 1
hsa04920 Adipocytokine signaling pathway 2 1
hsa00562 Inositol phosphate metabolism 2 1
hsa05146 Amoebiasis 2 1
hsa04916 Melanogenesis 2 1
hsa04080 Neuroactive ligand-receptor interaction 3 1
hsa04611 Platelet activation 2 1
hsa04152 AMPK signaling pathway 2 1
hsa04120 Ubiquitin mediated proteolysis 2 1
hsa04310 Wnt signaling pathway 2 1
Hiperdploidy
hsa05200 Pathways in cancer 65 0.00000743
hsa01521 EGFR tyrosine kinase inhibitor resistance 22 0.0000447
hsa04360 Axon guidance 35 0.0000607
hsa04728 Dopaminergic synapse 28 0.000106
hsa04015 Rap1 signaling pathway 38 0.000155
hsa04723 Retrograde endocannabinoid signaling 23 0.00023
hsa04151 PI3K-Akt signaling pathway 52 0.000262
hsa04261 Adrenergic signaling in cardiomyocytes 29 0.000294
hsa04724 Glutamatergic synapse 24 0.000403
hsa04713 Circadian entrainment 21 0.000655
Triploidy
hsa05213 Endometrial cancer 4 0.184
(Continued )
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Table 4. (Continued)
ID Name Number of Genes FDR
hsa05223 Non-small cell lung cancer 4 0.184
hsa05221 Acute myeloid leukemia 4 0.184
hsa04916 Melanogenesis 5 0.184
hsa04664 Fc epsilon RI signaling pathway 4 0.207
hsa04724 Glutamatergic synapse 5 0.207
hsa05100 Bacterial invasion of epithelial cells 4 0.255
hsa01521 EGFR tyrosine kinase inhibitor resistance 4 0.255
hsa04024 cAMP signaling pathway 6 0.274
hsa04072 Phospholipase D signaling pathway 5 0.274
https://doi.org/10.1371/journal.pone.0187422.t004
Fig 9. The unsupervised hierarchical clustering of the methylation level of a panel of 500 probes with
the largest differences in methylation level between different leukemia genetic subtypes.
https://doi.org/10.1371/journal.pone.0187422.g009
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erythroid and myeloid (including granulocytes, megakaryocytes and macrophages) or lym-
phoid cell line. The neoplastic transformation of early lymphoblastic progenitor cells in BCP
ALL dramatically changes their phenotype resulting in rapid proliferation and expansion.
These abnormal lymphoblasts quickly dominate in bone marrow cavities; comprising up to
100% of the bone marrow cells. Due to this, the population of bone marrow cells obtained
from patients with BCP ALL is practically homogenous compared to normal samples, where
many cells of different origin and of different developmental stage occur. In this second,
instance the poorly differentiated lymphocytic and myelocytic progenitors consist of up to 5%
bone marrow cellularity. Consequently, the differences of methylation profiles between BCP
ALL and normal bone marrow controls observed here-in can be explained by the heterogene-
ity of cells types in normal bone marrow, epigenetic control of the natural progenitor’s
Fig 10. Principal component analysis 3D plot based on 500 probes with the highest differences in methylation level among
genetic subtypes and remaining pre-B ALL patients. The plot is presented in three different layouts to enable visualization of separate
clusters.
https://doi.org/10.1371/journal.pone.0187422.g010
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development and with methylation changes dependent with neoplastic transformation in leu-
kemic samples.
The clear separation of DNA methylation profile between leukemic and normal bone mar-
row cells agrees with previous results [26–31]. Abnormal DNA methylation has been con-
firmed in many cancers including hematological neoplasms [32,33]. The role of DNA
methylation in hematopoietic regulation has also been established [34]. For example, DNA
methylation within bone marrow stem cells is important for their self-renewal and methylation
deficiency leads to their differentiation into myeloerythroid progenitors [35]. Epigenetic con-
trol also plays a key role in lymphoid B-cells development as shown by Almamun et al. [36].
The differences in DNA methylation pattern between leukemic and normal bone marrow
samples in our groups arise from many sites– 118,871 probes mapped to 17,885 unique genes
or intergenic regions. Among them, a slight domination of hypermethylated over hypomethy-
lated loci (56:44) in BCP ALL samples was revealed. Moreover, these DM sites are more
commonly associated with CpG islands and in close vicinity of transcription start sites. Inter-
estingly, the promoter-associated sites with different methylation were mainly (in 86,6% cases)
hypermethylated in leukemia when compared to healthy controls. This may result in altered
expression of many genes. The prevalence of differential hypermethylated promoter-associated
CpG islands compare to non-diseased samples was detected also in other studies [26,28,30].
Functional analysis of differential methylated genes (DMGs)
CpGs with distinct leukemic methylation were associated with 184 different genes (mainly
gene bodies). Those genes are enriched in several GO biological processes, of which the most
interesting appears to be: leukocyte activation (14 genes; adjP = 0.0097) or immune system
Fig 11. Methylation profile of ETV6 and RUNX1 genes in ETV6-RUNX1 subtype patients, remaining pre-B ALL cases and control
individuals. Red square marks the CpG fragments with large differences in methylation level between pre-B ALL and control samples.
https://doi.org/10.1371/journal.pone.0187422.g011
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process (32 genes; adjP = 0.0068). The genes were also over-represented in six different KEGG
pathways, including the “pathways in cancer” term (6 genes; adjP = 0.0043). When the Wiki-
Pathways terms were interrogated, the most enriched was associated with the integrated pan-
creatic cancer pathway (5 genes; adjP = 0.0011).
The most meaningful results were however obtained, when terms from the PharmGKB
database of disease phenotypes were analyzed. Several consistent disease phenotypes have
been enriched by the analyzed genes, including: lymphoma, B-cell lymphoma, lymphoproli-
ferative disorders, lymphatic diseases, lymphoid leukemia and leukemia (Table 6; S6
Appendix).
When 124 genes related with hypermethylated CpGs were screened separately for their
functions, only a single KEGG pathway was found to be significant and is related to protein
processing in endoplasmic reticulum (4 genes; adjP = 0.0030). The hypermethylated genes
were also enriched in several disease phenotypes with one which could be directly connected
with cancer, namely: hepatocellular carcinoma phenotype (4 genes; adjP = 0.0075).
When the remaining 60 genes associated with hypomethylated sites were analyzed sepa-
rately, no enriched biological processes, molecular functions or pathways were found. How-
ever, all previously mentioned lymphoma/leukemia associated disease phenotypes were
enriched by this gene category.
The analyzed promoter regions were associated with 2045 different genes. The annotation
analysis showed, that hypermethylated probes were found within putative promoter regions of
1540 genes and hypomethylated sites were associated with 518 genes. When the genes were
analyzed jointly in terms of their functional relevance, several general biological processes or
Fig 12. Methylation profile of TCF3 and PBX1 genes in TCF3-PBX1 subtype patients, remaining pre-B ALL cases and control
individuals. Red square marks the CpG fragments with large differences in methylation level between pre-B ALL and control samples.
https://doi.org/10.1371/journal.pone.0187422.g012
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processes connected with nervous system functioning and development have been detected,
including e.g.: nervous system development, single-multicellular organism process, neuron
differentiation, neurogenesis, cell-cell signaling and many others. Among the top ten signifi-
cantly enriched KEGG pathways there were those associated, for example, with neuroactive
ligand-receptor interaction (68 genes; adjP = 4.21e-30), calcium signaling (36 genes;
Table 5. The most important DM sites in patients from particular BCP ALL subgroups extracted using the lasso penalized logistic regression
analysis.
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adjP = 6.73e-13) or pathways in cancer (34 genes; adjP = 6.29e-05). Among the top ten
enriched disease phenotypes, no leukemia-related disorders were found. When genes with
hyper- and hypomethylated promoters were analyzed separately, however, we find that the
hypermethylated genes are enriched in disease phenotypes associated with nervous system and
mental disorders, and that the hypomethylated genes are enriched several disease phenotypes,
like e.g.: lymphoproliferative disorders, lymphoid leukemia, B-Cell lymphoma, Lymphoid
leukemia NOS, lymphatic diseases, general leukemia or B-Cell leukemia (Table 6 and S7
Appendix).
The results of other studies have revealed that the spectrum of genes with potentially aber-
rated methylation in BCP ALL is very wide and includes many biological processes. These pro-
cesses include, among others, growth and proliferation’s regulation [26,29–31], apoptosis
[26,29,30,37] hematopoiesis and lymphocyte B development [27,28,36] and immune response
[38]. It must be noted that alteration of promoter DNA methylation does not have to translate
to major changes in gene expression in any case [26].
The impact of methylation signature on prognosis in BCP ALL
The discovery of new molecular prognostic factors is important for further therapy individual-
ization and optimization. The meaningful differences in genes methylation between HR and
IR/SR BCP ALL patients were depended with both: promoters as well as gene bodies regions.
Promoter region-related sites were connected with PSMF1 and DIP2B genes, whereas differen-
tial methylation of CpGs within gene bodies was found in NGFR, ADAMTS20 and MBP genes.
Although there was not enough data for conclusive results we also tried to extract the differ-
ences between methylation of single/multiple genes in patients stratified by risk group. We
observe only minimal differences between count of DM CpG sites in HRG and IRG/SRG
patients but it was possible to distinguish seven DM sites which could be the biomarkers of the
HR group. The risk prediction based on these 7 DM sites might be determined early, before
therapy response assessment. Two of these 7 sites, are localized in gene body/promoter
regions, and thus may have potential functional roles in regulating the expression of MBP and
Table 6. Selected disease phenotypes enriched by genes associated with uniform leukemia methylation pattern.
Disease Disease ID adjP Genes
Lymphoma DB_ID:PA444840 1.06E-
05
CXCR5, NCOR2, TNFAIP3, IL7R, TRAF2, RUNX1, CD27, FOXP1, EML4,
MME, NBN
Lymphoma, B-Cell DB_ID:PA446304 1.60E-
05
CXCR5, NCOR2, TNFAIP3, IL7R, TRAF2, RUNX1, CD27, FOXP1, MME
Cancer or viral infections DB_ID:
PA128407012
0.0002 MX1, TIMP2, HIF1A, ERCC3, NDRG1, FANCD2, RUNX1, BLM, FOXP1,
EML4, MME, IFITM1, SMARCB1, NBN
Lymphoma, Low-Grade DB_ID:PA446307 0.0002 CXCR5, TNFAIP3, CD27, FOXP1, TRAF2, MME, NBN
Lymphoma, B-Cell, Marginal Zone DB_ID:PA446727 0.0002 TNFAIP3, CD27, FOXP1, TRAF2
Lymphoproliferative Disorders DB_ID:PA444849 0.0002 CXCR5, TNFAIP3, IL7R, TRAF2, RUNX1, CD27, FOXP1, MME, NBN
Lymphatic Diseases DB_ID:PA444833 0.0002 CXCR5, TNFAIP3, IL7R, TRAF2, RUNX1, CD27, FOXP1, MME, NBN
Lymphoma, Non-Hodgkin DB_ID:PA444845 0.0004 CXCR5, TNFAIP3, CD27, BLM, TRAF2, NBN
Virus Diseases DB_ID:PA446038 0.0006 MX1, CXCR5, ITGAL, IL7R, TANK, PSMB7, PIK3CD, CD27, IFITM1
Leukemia, Lymphoid DB_ID:PA444756 0.0006 CXCR5, RUNX1, BRE, CD27, IL7R, MME, LINC00598
Lymphoid leukemia NOS DB_ID:
PA165108377
0.0006 CXCR5, RUNX1, BRE, CD27, IL7R, MME, LINC00598
Precursor Cell Lymphoblastic Leukemia-
Lymphoma
DB_ID:PA446155 0.001 RUNX1, IL7R, MME, LINC00598, NBN
Leukemia DB_ID:PA444750 0.0018 CXCR5, NCOR2, RUNX1, BLM, CD27, SENP1, MME, NBN
https://doi.org/10.1371/journal.pone.0187422.t006
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PSMF1 genes. [Table 5]. The protein encoded by the classic MBP gene is a major constituent
of the myelin sheath of oligodendrocytes and Schwann cells in the nervous system. However,
MBP-related transcripts are also present in the bone marrow and the immune system [39].
The MBP has also an important role to play in apoptosis [40]. It has been shown that MBP
SNP rs3794845 is significantly associated with childhood ALL risk [41]. PSMF1 gene encodes a
protein that inhibits the activation of the proteasome by the 11S and 19S regulators (provided
by apoptotic and cell cycle mechanisms). Proteasome inhibitors (for example bortezomib)
enhance many conventional therapies, also in ALL [42]. Although there are some limitations
including small sample size and a lack of genes’ expression information supporting the aber-
rated DM sites methylation, our study identified two genes with potential impact on childhood
ALL prognosis.
Global promoter methylation profiling has been previously demonstrated to all subgroup-
ing and prognostication of pediatric ALL in T cells phenotype ALL [43,44]. Takeuchi et al [45]
revealed that patients from medium/high risk group had multiple genes methylated compared
to those from low risk but they included patients with both, B- and T-cells ALL together. No
specific methylation profile characteristic for HRG was observed in our study. The relationship
between methylation and outcome prognosis or relapse risk in pediatric BCP ALL is unproven.
Some authors [28,30,46] have identified some genes with aberrant methylation relevant to
relapse prediction but others [38] reached opposing conclusions and didn’t find any statisti-
cally significant associations between methylation level of any CpGs and subsequent relapse of
BCP ALL.
Epigenetic landscape and cytogenetic subtypes in childhood BCP ALL
Our study confirmed the distinguishable differences in the general methylation pattern
between the analyzed cytogenetic subsets of patients. It was possible to clearly separate genetic
leukemia subtypes associated with ETV6-RUNX1 and TCF3-PBX1 variants with visible separa-
tion of clusters including hyperdiploidy cases and separation of the single case with IGH/trip-
loidy aberrations. These findings are consistent with observations from other studies
[30,38,47] where the cytogenetic subtypes showed a clear correlation with methylation profile
but this clustering was not absolute.
The lack of clear differences in methylation level of genes involved in chromosomal translo-
cations between BCP ALL patients with- or without specific rearrangement, suggest that the
translocation and change of genes’ sequence context does not affect methylation and that
methylation seems not to be a mechanism for the regulation of expression of the resulting
fusion genes. The methylation profile of some of these genes, however, show signs of alteration
between healthy and leukemia samples.
Methylation sites with potential significant different methylation status specifically depended
on analyzed cytogenetic status. Only a few of these sites are in gene bodies or promoter regions.
Their functional role stays unknown but they may be potentially used as biomarker of ALL
patients with hyperdiploidy or t(12;21) and should be confirmed in future studies with a larger
cohort of patients. Genes specifically correlated with analyzed cytogenetic subsets (listed in
Table 5) may be suitable targets for the searching new individualized BCP ALL therapy.
Conclusions
The clear separation of DNA methylation profile between leukemic and normal bone marrow
cells was confirmed. The analyzed translocations and change of genes’ sequence context does
not affect methylation thus methylation seems not to be a mechanism for the regulation of
expression of the resulting fusion genes. Moreover, it was possible to distinguish some DM
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sites which could be the biomarkers of the BFM ALL IC 2009 high risk group as well as hyper-
diploidy and t(12;21) ETV6-RUNX1 carriers.
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